BiotechTube

YM087

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hyponatremia

Conditions

Hyponatremia

Trial Timeline

Aug 1, 2000 → Feb 1, 2003

NCT ID
NCT00380575

About YM087

YM087 is a phase 3 stage product being developed by Astellas Pharma for Hyponatremia. The current trial status is completed. This product is registered under clinical trial identifier NCT00380575. Target conditions include Hyponatremia.

What happened to similar drugs?

1 of 7 similar drugs in Hyponatremia were approved

Approved (1) Terminated (4) Active (3)
✅ConivaptanAstellas PharmaApproved
❌ConivaptanAstellas PharmaPhase 3
❌Satavaptan + placeboSanofiPhase 3
🔄lixivaptan + PlaceboBiogenPhase 3
❌LixivaptanBiogenPhase 3
🔄lixivaptan + placeboBiogenPhase 3
🔄Lixivaptan + PlaceboBiogenPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00380575Phase 3Completed

Competing Products

9 competing products in Hyponatremia

See all competitors
ProductCompanyStageHype Score
ConivaptanAstellas PharmaApproved
35
ConivaptanAstellas PharmaPhase 3
32
Tolvaptan + PlaceboJiangsu Hengrui MedicinePhase 2/3
34
Satavaptan + placeboSanofiPhase 3
32
lixivaptan + PlaceboBiogenPhase 3
37
LixivaptanBiogenPhase 3
29
lixivaptan + placeboBiogenPhase 3
37
Lixivaptan + PlaceboBiogenPhase 3
37
PEG-SD + PEG-ELSBausch HealthPre-clinical
20